ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Methoxydimethyltryptamines

Also written as “5 Methoxy N,N Dimethyltryptamine”, “GH001” and “BMND08”.

Its studies are mostly in Depressive Disorder, Treatment-Resistant · Mood Disorders · Depression, Postpartum · Bipolar Disorder, led by 3 companies.

Drug pageMethoxydimethyltryptamines: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Nov 17, 202011 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GH Research Irelandits history only90 open or runningphase 2since Nov 17, 2020Nov 12, 2020none ahead
Biomind Labsits history only10 open or runningphase 2since Dec 10, 2024Dec 10, 2024none ahead
Eli Lilly10 open or runningphase 1since Aug 24, 2021Aug 24, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2021First study: phase 1 study in Pharmacokinetics in Healthy AdultsFirst studyNCT05032833 · 36 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05032833Pharmacokinetics in Healthy Adults · United Kingdom1CompletedJul 7, 202236

How it is read

Names in the registry

  • “5 Methoxy N,N Dimethyltryptamine”, 6 entries
  • “GH001”, 3 entries
  • “BMND08”, 1 entry
  • “5-MeO-DMT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.